- | Country : -
- | organs : -
- | Specialty : -
Extract
The primary objective is to evaluate the safety and efficacy of the treatment with BAY 81-8973 for prophylaxis and treatment of breakthrough bleeds in children with haemophilia A
Inclusion criteria
- Severe hemophilia A (< 1% FVIII:C)